S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
NYSE:AMAM

Ambrx Biopharma (AMAM) Stock Forecast, Price & News

$11.66
+0.33 (+2.91%)
(As of 09/20/2023 ET)
Compare
Today's Range
$11.18
▼
$12.20
50-Day Range
$9.30
▼
$15.84
52-Week Range
$0.38
▼
$16.86
Volume
617,055 shs
Average Volume
1.89 million shs
Market Capitalization
$723.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.57
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Ambrx Biopharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
93.6% Upside
$22.57 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Ambrx Biopharma in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$19.63 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.24) to ($1.17) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

382nd out of 962 stocks

Biological Products, Except Diagnostic Industry

51st out of 156 stocks

See Top Rated MarketRank™ Stocks Here

AMAM stock logo

About Ambrx Biopharma (NYSE:AMAM) Stock

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company's lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. It is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, the company is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

AMAM Price History

AMAM Stock News Headlines

September 21, 2023 | americanbankingnews.com
Cormorant Asset Management, Lp Buys 751,233 Shares of Ambrx Biopharma Inc. (NYSE:AMAM) Stock
September 21, 2023 | americanbankingnews.com
Cormorant Asset Management, Lp Acquires 1,401,505 Shares of Ambrx Biopharma Inc. (NYSE:AMAM) Stock
September 21, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 21, 2023 | americanbankingnews.com
Ambrx Biopharma (NYSE:AMAM) Shares Gap Up Following Insider Buying Activity
September 19, 2023 | americanbankingnews.com
Ambrx Biopharma (NYSE:AMAM) Stock Rating Reaffirmed by Cantor Fitzgerald
September 19, 2023 | americanbankingnews.com
Ambrx Biopharma Inc. (NYSE:AMAM) Given Average Rating of "Moderate Buy" by Brokerages
September 18, 2023 | finance.yahoo.com
Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
September 17, 2023 | americanbankingnews.com
Ambrx Biopharma (NYSE:AMAM) Shares Gap Down to $9.94
September 21, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 15, 2023 | nasdaq.com
Goldman Sachs Maintains Ambrx Biopharma Inc - ADR (AMAM) Neutral Recommendation
September 15, 2023 | americanbankingnews.com
Ambrx Biopharma (NYSE:AMAM) Price Target Raised to $10.00 at The Goldman Sachs Group
September 13, 2023 | markets.businessinsider.com
Where Ambrx Biopharma Stands With Analysts
September 13, 2023 | americanbankingnews.com
Ambrx Biopharma (NYSE:AMAM) Now Covered by Analysts at BTIG Research
September 5, 2023 | finance.yahoo.com
Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences
August 31, 2023 | msn.com
Ambrx Biopharma Has Surged 524% This Year. But It Could Just Be Getting Started.
August 21, 2023 | msn.com
Promising Developments In Ambrx's Engineered Precision Biologics
August 16, 2023 | msn.com
Cantor Fitzgerald Reiterates Ambrx Biopharma Inc - ADR (AMAM) Overweight Recommendation
August 12, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ambrx Biopharma (AMAM), QuidelOrtho (QDEL) and Aveanna Healthcare Holdings (AVAH)
August 1, 2023 | msn.com
RBC Capital Initiates Coverage of Ambrx Biopharma Inc - ADR (AMAM) with Outperform Recommendation
August 1, 2023 | finance.yahoo.com
Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs
July 31, 2023 | markets.businessinsider.com
Unique ADC Constructs Boost Ambrx Biopharma's Profile: Analyst Sees Optimistic Outlook
July 28, 2023 | finance.yahoo.com
Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023
July 19, 2023 | msn.com
Ambrx Biopharma wins FDA fast track tag for prostate cancer therapy
July 19, 2023 | finance.yahoo.com
FDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 15, 2023 | sg.finance.yahoo.com
Ambrx Biopharma Inc. (AMAM)
June 28, 2023 | finance.yahoo.com
Ambrx Announces Closing of $75 Million Market Priced Registered Offering
June 21, 2023 | au.finance.yahoo.com
AMAM - Ambrx Biopharma Inc.
See More Headlines
Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

AMAM Company Calendar

Last Earnings
8/09/2023
Today
9/20/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:AMAM
CUSIP
N/A
CIK
1836056
Web
ambrx.com
Phone
858-875-2400
Fax
N/A
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.57
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+93.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.28
Quick Ratio
13.28

Sales & Book Value

Annual Sales
$7.40 million
Price / Sales
97.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.05 per share
Price / Book
3.82

Miscellaneous

Outstanding Shares
62,010,000
Free Float
61,613,000
Market Cap
$723.04 million
Optionable
Not Optionable
Beta
-2.66
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Daniel J. O'Connor J.D. (Age 58)
    CEO, Pres & Director
    Comp: $509.94k
  • Ms. Sonja Nelson CPA (Age 50)
    Chief Financial Officer
    Comp: $1.18M
  • Mr. Andrew P. Aromando (Age 54)
    Chief Operating Officer
  • Dr. Ying J. Buechler Ph.D.
    Chief Technology Officer
  • Dr. Shawn Shao-Hui Zhang Ph.D.
    Chief Scientific Officer & GM of China
  • Mr. Jared Kelly
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Robert Azzara
    VP of Human Capital
  • Dr. Sandra Aung Ph.D.
    Chief Clinical Officer
  • Ms. Renu Vaish M.Sc. (Age 56)
    Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AMAM Stock - Frequently Asked Questions

Should I buy or sell Ambrx Biopharma stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMAM shares.
View AMAM analyst ratings or view top-rated stocks.

What is Ambrx Biopharma's stock price forecast for 2023?

7 analysts have issued 12-month target prices for Ambrx Biopharma's stock. Their AMAM share price forecasts range from $10.00 to $30.00. On average, they predict the company's share price to reach $22.57 in the next twelve months. This suggests a possible upside of 93.6% from the stock's current price.
View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts.

How have AMAM shares performed in 2023?

Ambrx Biopharma's stock was trading at $2.27 on January 1st, 2023. Since then, AMAM shares have increased by 413.7% and is now trading at $11.66.
View the best growth stocks for 2023 here.

How were Ambrx Biopharma's earnings last quarter?

Ambrx Biopharma Inc. (NYSE:AMAM) released its earnings results on Wednesday, August, 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.23. The firm had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.50 million.

What ETFs hold Ambrx Biopharma's stock?

ETFs with the largest weight of Ambrx Biopharma (NYSE:AMAM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Ambrx Biopharma IPO?

(AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen acted as the underwriters for the IPO.

What is Ambrx Biopharma's stock symbol?

Ambrx Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMAM."

Who are Ambrx Biopharma's major shareholders?

Ambrx Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cormorant Asset Management LP (15.57%), Commodore Capital LP (5.14%), VR Adviser LLC (4.50%), Holocene Advisors LP (1.48%), ExodusPoint Capital Management LP (0.86%) and Point72 Asset Management L.P. (0.57%).
View institutional ownership trends.

How do I buy shares of Ambrx Biopharma?

Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ambrx Biopharma's stock price today?

One share of AMAM stock can currently be purchased for approximately $11.66.

How much money does Ambrx Biopharma make?

Ambrx Biopharma (NYSE:AMAM) has a market capitalization of $723.04 million and generates $7.40 million in revenue each year.

How can I contact Ambrx Biopharma?

The official website for the company is ambrx.com. The company can be reached via phone at 858-875-2400 or via email at ir@ambrx.com.

This page (NYSE:AMAM) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -